Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.
Palii SS, Afzal A, Shaw LC, Pan H, Caballero S, Miller RC, Jurczyk S, Reubi JC, Tan Y, Hochhaus G, Edelhauser H, Geroski D, Shapiro G, Grant MB.
Palii SS, et al. Among authors: pan h.
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):5094-102. doi: 10.1167/iovs.08-2289. Epub 2008 Jul 3.
Invest Ophthalmol Vis Sci. 2008.
PMID: 18599562